Home » Stocks » DBTX

Decibel Therapeutics, Inc. (DBTX)

Stock Price: $8.91 USD 0.00 (0.00%)
Updated Jun 11, 2021 4:00 PM EDT - Market closed
Market Cap 221.88M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 12.11M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 11
Last Price $8.91
Previous Close $8.91
Change ($) 0.00
Change (%) 0.00%
Day's Open 8.80
Day's Range 8.70 - 9.38
Day's Volume 48,289
52-Week Range 6.18 - 24.39

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Is investor enthusiasm for new biotechnology companies waning? Based on the performance of the 35 biotechs that went public in the first quarter, that may be the case.

Other stocks mentioned: EWTX, RXRX, TAK
1 week ago - GuruFocus

Adds leaders with expertise in hearing loss and balance disorders, combined with experience in gene therapy development Adds leaders with expertise in hearing loss and balance disorders, combined with e...

2 weeks ago - GlobeNewsWire

BOSTON, May 19, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and impr...

3 weeks ago - GlobeNewsWire

– Established cGMP manufacturing and development agreement with Catalent for otoferlin dual-vector gene therapy, DB-OTO –

1 month ago - GlobeNewsWire

BOSTON, April 08, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and im...

2 months ago - GlobeNewsWire

-Successfully completed an oversubscribed Series D financing and upsized Initial Public Offering raising approximately $220.1M in gross proceeds-

2 months ago - GlobeNewsWire

Decibel Therapeutics Inc (NASDAQ: DBTX) presented preclinical data of its gene therapy candidate, DB-OTO, for hearing loss due to mutation of the otoferlin gene. Decibel presented the data at the Annual...

3 months ago - Benzinga

Podium presentations and posters shared at the 44th Annual Association for Research in Otolaryngology Conference Podium presentations and posters shared at the 44th Annual Association for Research in Ot...

3 months ago - GlobeNewsWire

Insider buying can be an encouraging signal for potential investors, especially when markets face uncertainty. Biotech stocks and secondary and initial public offerings were well represented this week.

Other stocks mentioned: BMBL, FISV, ATEX, CRVS, MTEM, NEXI, ONCR ...
3 months ago - Benzinga

BOSTON, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and imp...

3 months ago - GlobeNewsWire

Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and...

4 months ago - GlobeNewswire

Catalent will offer materials from its gene therapy facilities in Maryland to support IND-enabling studies and a Phase I/II clinical trial of the product.

4 months ago - PharmTech

Qualifying children will have free access to Invitae's Comprehensive Deafness Panel, which assesses multiple genes linked to syndromic and non-syndromic deafness.

4 months ago - GenomeWeb

Decibel Therapeutics, a Phase 1 biotech developing treatments for hearing and balance disorders, filed on Friday with the SEC to raise up to $75 million in an initial public offering.

4 months ago - NASDAQ

Decibel Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.

4 months ago - SEC

...Decibel Therapeutics announced the closing of an oversubscribed Series D financing, which raised $82.2M.

5 months ago - The Hearing Journal

BOSTON--Decibel Therapeutics, a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that th...

5 months ago - Business Wire

About DBTX

Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments for hearing and balance disorders, one of the largest areas of unmet need in medicine. We have built a proprietary platform that integrates single-cell genomics and bioinformatics analyses, precision gene therapy technologies and our expertise in inner ear biology. We are leveraging our platform to advance our pipeline of preclinical gene therapy programs that are designed to selectively replace genes for the treatmen... [Read more...]

Industry
Biotechnology
IPO Date
Feb 12, 2021
CEO
Laurence Reid, Ph.D.
Employees
40
Stock Exchange
NASDAQ
Ticker Symbol
DBTX
Full Company Profile

Financial Performance

Financial Statements